GOSS Gossamer Bio
- 0.542
- +0.022+4.29%
Gossamer Bio News
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Gossamer Bio Is Maintained at Buy by Goldman Sachs
Express News | Gossamer Bio Shares Are Trading Higher After Competitor Aerovate Therapeutics Reported Topline Results From the Phase 2b Portion of IMPAHCT Trial of AV-101 for Pulmonary Arterial Hypertension
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
Goldman Sachs analyst Paul Choi maintains $Gossamer Bio(GOSS.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 0.0% and a total
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAutonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNC
Buy Rating Reaffirmed for Gossamer Bio on Seralutinib's Promising Clinical Data and Future Prospects
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Gossamer Bio (NASDAQ:GOSS) with a Buy and maintains $10 price target.
Express News | Gossamer Bio to Provide Updated Seralutinib Torrey Open-Label Extension Data at the American Thoracic Society 2024 International Conference
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
PDF Version SAN DIEGO--(BUSINESS WIRE)--May 14, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAesthetic Medical Intl (NASDAQ:AIH) shares moved upwards by 23.3% to $0.57 during Monday's after-market session. The market value of their outstanding shares is at $27.0 million. Harrow (NASDAQ
Express News | Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Chiesi Y Gossamer Bio Anuncian Una Colaboración Global Para Desarrollar Y Comercializar Seralutinib
Chiesi y Gossamer Bio anuncian una colaboración global transformadora para desarrollar y comercializar seralutinib en la hipertensión arterial pulmonar y otras indicaciones respiratorias Colaborac
Chiesi Et Gossamer Bio Annoncent Une Collaboration Mondiale Transformatrice Pour Développer Et Commercialiser Le Séralutinib Pour L'hypertension Artérielle Pulmonaire Et D'autres Indications Respiratoires
Collaboration stratégique pour tirer parti de l'héritage de leadership dans les maladies respiratoires de Chiesi et de l'expertise de Gossamer Bio en matière de développement pour l'hypertension
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PDF Version SAN DIEGO--(BUSINESS WIRE)--May 10, 2024-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutini
Buy Rating Affirmed for Gossamer Bio Amidst Strategic Collaboration and Market Opportunity Growth
Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush
Gossamer Bio Price Target Maintained With a $4.00/Share by Wedbush
Express News | Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Strategic Partnership and Financial Upside: Gossamer Bio Earns a Buy Rating
Gossamer Bio | 10-Q: Quarterly report
Gossamer Bio: Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in 4Q 2025 >GOSS
Gossamer Bio: Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in 4Q 2025 >GOSS
Express News | Gossamer Bio Inc: Sees Current Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Operating, Capital Expenditures Into H1 2027
Analysis
Price Target
No Data
